$130.54
0.66%The underlying index, which is composed of common stocks of 30 U.S. pharmaceutical companies. Under normal circumstances, at least 80% of the value of its net assets, plus the amount of any borrowings for investment purposes, in securities of companies engaged in the pharmaceuticals industry, and in derivatives and other investments that have economic characteristics similar to securities of companies engaged in the pharmaceuticals industry (the “80% investment policy”). The fund is non-diversified.
Quality against peers; 50 is the peer median.
PM peer median: the typical company the value is compared with. The /100 is its score against those peers.